Results 101 to 110 of about 1,651 (123)

Epidemiology of Infections Caused by Gram-Positive Cocci-<i>Staphylococcus aureus</i>, <i>Streptococcus pneumoniae</i> and <i>Enterococcus faecium</i>: Antibiotic Resistance and Future Prospects. [PDF]

Microorganisms
Birlutiu V, Birlutiu RM.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties

Open Forum Infectious Diseases, 2022
Martin Krsak, Mark Redell, Kyle C Molina
exaly  

In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013

Diagnostic Microbiology and Infectious Disease, 2014
James A. Karlowsky, G G Zhanel
exaly  

activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015

Diagnostic Microbiology and Infectious Disease, 2017
Greg Moeck, James A. Karlowsky
exaly  

activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci

Diagnostic Microbiology and Infectious Disease, 2018
Melissa Karau
exaly  

Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review

International Journal of Antimicrobial Agents, 2020
Andrés F Henao-Martínez, Daniel B Chastain   +1 more
exaly  

Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

Clinical Infectious Diseases, 2015
Greg Moeck, G Ralph Corey
exaly  

Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains

International Journal of Antimicrobial Agents, 2010
Emilio Bouza, Almudena Burillo
exaly